Diagnosis and clinical use of bromperidol in HIV-related psychoses in a sample of seropositive patients with brain damage.
We evaluated in an open trial the safety and effectiveness of a high-potency neuroleptic (bromperidol) for the treatment of AIDS-related organic mental syndromes. Eleven (nine men and two women) seropositive patients with psychotic features were included; six were intravenous drug users (IVDU) and five were not IVDU (NON-IVDU). On the basis of the achievement of a CGI score of 1 or 2 (much improved or very much improved) at the fourth week, nine patients were considered responders, one was a partial responder and one was a non-responder. From a clinical point of view, "positive" psychotic symptoms had a significant remission, while the "negative" ones seemed to be less sensitive or insensitive to bromperidol treatment.
Perretta
P
P
Psychiatric Clinic II, University of Pisa, Italy.
Nisita
C
C
Zaccagnini
E
E
Scasso
A
A
Nuccorini
A
A
Santa
M D
MD
Cassano
G B
GB
D015526:AIDS Dementia Complex / Q000188:drug therapy* / Q000523:psychology; D000328:Adult; D005260:Female; D006679:HIV Seropositivity / Q000523:psychology*; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D015819:Substance Abuse, Intravenous
D006220:Haloperidol; C006820:bromperidol